Fermenta Biotech Ltd — Important, 26-05-2026: Company Update

Fermenta Biotech reported strong audited results for FY26, with consolidated revenue hitting INR 547.8 Cr (+14% YoY). Excluding real estate, core business revenue grew 26% to INR 538.4 Cr, with EBITDA soaring 44% to INR 120 Cr, primarily driven by robust Vitamin D3 human nutrition sales. While reported PAT of INR 70.3 Cr was down 8% YoY, this reflects a higher base from a one-time real estate income in the prior year. The company's board has proposed a dividend of Rs 3.75 per share, reflecting confidence in its sustained turnaround and upcoming product launches.